Genesis Therapeutics and Gilead Sciences partner to develop small molecule therapies using AI platform GEMS, with Gilead providing $35M upfront and potential milestone payments.

Genesis Therapeutics and Gilead Sciences have formed a strategic partnership to develop small molecule therapies using Genesis' AI platform, GEMS. Gilead will provide an upfront payment of $35 million and can nominate additional targets, while Genesis may earn milestone payments and royalties from successful products. The collaboration aims to expedite drug development for challenging targets, with Gilead retaining exclusive rights to clinical development and commercialization.

September 10, 2024
10 Articles